Dezamizumab - GlaxoSmithKline

Drug Profile

Dezamizumab - GlaxoSmithKline

Alternative Names: GSK-2398852

Latest Information Update: 07 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pentraxin Therapeutics
  • Developer GlaxoSmithKline
  • Class Monoclonal antibodies
  • Mechanism of Action Serum amyloid P component inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyloidosis

Most Recent Events

  • 23 Aug 2018 GlaxoSmithKline suspends phase I trial in Amyloidosis (Combination therapy) in Sweden (IV) (NCT03417830)
  • 22 Aug 2018 GlaxoSmithKline suspends patient enrolment due to pending data review in a phase II trial in Amyloidosis (Combination therapy) in USA and United Kingdom (IV) (NCT03044353)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top